Joseph A Johnston
Overview
Explore the profile of Joseph A Johnston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
1287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boustani M, Doty E, Garrison Jr L, Smolen L, Klein T, Murphy D, et al.
Neurol Ther
. 2024 Sep;
13(6):1641-1659.
PMID: 39292433
Introduction: The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer's disease (AD) in the United...
2.
Chandler J, Ye W, Mi X, Doty E, Johnston J
J Alzheimers Dis
. 2024 Jun;
100(2):563-578.
PMID: 38875031
Background: Impact of Alzheimer's disease (AD) progression on patient health-related quality of life (HRQoL), caregiver time, and societal costs is not well characterized in early AD. Objective: To assess the...
3.
Brnabic A, Curtis S, Johnston J, Lo A, Zagar A, Lipkovich I, et al.
PLoS One
. 2024 Mar;
19(3):e0300708.
PMID: 38517926
Researchers are increasingly using insights derived from large-scale, electronic healthcare data to inform drug development and provide human validation of novel treatment pathways and aid in drug repurposing/repositioning. The objective...
4.
Boustani M, Doty E, Garrison Jr L, Smolen L, Belger M, Klein T, et al.
Clin Ther
. 2022 Oct;
44(11):1449-1462.
PMID: 36210219
Purpose: Clinical trials have produced promising results for disease-modifying therapies (DMTs) for Alzheimer's disease (AD); however, the evidence on their potential cost-effectiveness is limited. This study assesses the cost-effectiveness of...
5.
Wessels A, Belger M, Johnston J, Yu Y, Rentz D, Dowsett S, et al.
J Alzheimers Dis
. 2022 Jun;
88(2):577-588.
PMID: 35694928
Background: The integrated Alzheimer's Disease Rating Scale (iADRS) is a validated cognitive/functional composite that effectively captures cognitive and functional decline over a broad spectrum of disease. The clinical meaningfulness of...
6.
Currie B, Howell T, Matza L, Cox D, Johnston J
Diabetes Ther
. 2021 Sep;
12(11):2827-2856.
PMID: 34554411
Introduction: In recent decades, the dramatic rise of obesity among youth in the US has been accompanied by a rise in the prevalence of type 2 diabetes (T2D) in this...
7.
Johnston J, Nelson D, Bhatnagar P, Curtis S, Chen Y, MacKrell J
PLoS One
. 2021 Feb;
16(2):e0247683.
PMID: 33621267
Essential fructosuria (EF) is a benign, asymptomatic, autosomal recessive condition caused by loss-of-function variants in the ketohexokinase gene and characterized by intermittent appearance of fructose in the urine. Despite a...
8.
Johnston J, Nelson D, Zhang L, Curtis S, Voelker J, Wetterau J
PLoS One
. 2019 Jun;
14(6):e0218435.
PMID: 31246994
Evidence of involvement of novel biomarkers in disease pathogenesis from research cohorts often precedes an understanding of their distributions in broader populations. This study aimed to estimate the distribution of...
9.
Stewart K, Johnston J, Matza L, Curtis S, Havel H, Sweetana S, et al.
Patient Prefer Adherence
. 2016 Aug;
10:1385-99.
PMID: 27528802
Purpose: Pharmaceutical formulation and treatment process attributes, such as dose frequency and route of administration, can have an impact on quality of life, treatment adherence, and disease outcomes. The aim...
10.
Jalbert J, Nguyen L, Gerhard-Herman M, Kumamaru H, Chen C, Williams L, et al.
Circ Cardiovasc Qual Outcomes
. 2016 Apr;
9(3):275-85.
PMID: 27116974
Background: Effectiveness of carotid artery stenting (CAS) relative to carotid endarterectomy (CEA) among Medicare patients has not been established. We compared effectiveness of CAS versus CEA among Medicare beneficiaries. Methods...